AMLX
Amylyx Pharmaceuticals Inc
33.90$
+4.0%
vs. previous close
Closing price · As of: Sep 17, 2026
Filings
Filings
Listed US companies must report material events to the Securities and Exchange Commission. This page lists the filings of Amylyx Pharmaceuticals Inc (AMLX) with date, type and a link to the original document.
| Date | Type | Filing | Original |
|---|---|---|---|
| 09/11/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/11/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/11/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/11/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/11/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
| 09/08/2026 | Current report (8-K) | Amylyx Pharmaceuticals, Inc. (AMLX): Entry into a Material Definitive Agreement | View report ↗ |
| 08/20/2026 | Current report (8-K) | Amylyx Pharmaceuticals, Inc. (AMLX): Entry into a Material Definitive Agreement; Financial Statements and Exhibits | View report ↗ |
| 08/20/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 08/18/2026 | Current report (8-K) | Amylyx Pharmaceuticals, Inc. (AMLX): Other Events; Financial Statements and Exhibits | View report ↗ |
| 08/18/2026 | Current report (8-K) | Amylyx Pharmaceuticals, Inc. (AMLX): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View report ↗ |
| 08/18/2026 | Capital measure | Form 424B5 filed with the SEC | View document ↗ |
| 08/06/2026 | Current report (8-K) | Amylyx Pharmaceuticals, Inc. (AMLX): Results of Operations and Financial Condition; Financial Statements and Exhibits | View report ↗ |
| 07/09/2026 | Insider sale notice | Form 144 filed with the SEC | View document ↗ |
Showing the 100 most recent filings of the selected type.
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Filings: SEC EDGAR
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.